Telesis Bio reports Q3 EPS (42c), consensus (48c)

Reports Q3 revenue $6.68M, consensus $5.3M. Nelson continued, "Beginning in Q1 of 2023 we will release additional BioXp(R) kits that will enable scientists to begin the cloning, amplification, and mRNA synthesis process from the customer’s own linear DNA or plasmid DNA. We believe providing scientists the flexibility to begin with their own materials as an optional starting point will further expand the utility, speed, and impact of our systems. This will allow us to deliver increased value to our customers and to access a significantly larger portion of the customer base. The new kits will also position us well to take increased share of the synthetic biology and multiomics markets, while at the same time growing our revenue, and improving our margins."